Natriuretic Peptide-Guided Therapy for Heart Failure
Natriuretic Peptides
894 patients
Enrolled in GUIDE-IT before it was stopped early for futility. The largest NP-guided therapy trial found no benefit over usual care in HFrEF.
Felker et al., JAMA, 2017
Felker et al., JAMA, 2017
View as imageHeart failure affects over 60 million people globally, and treatment involves layering multiple medications at optimal doses. The question behind natriuretic peptide-guided therapy is straightforward: can serial measurements of BNP or NT-proBNP tell clinicians when medications are working, when they need adjustment, and when a patient is deteriorating before symptoms appear? The concept is appealing because natriuretic peptides directly reflect cardiac wall stress. Higher levels mean the heart is under greater hemodynamic load. Lower levels mean treatment is reducing that load. After two decades of clinical trials, the answer is more complicated than anyone expected.
Key Takeaways
- The GUIDE-IT trial (894 patients, HFrEF) was stopped early because NT-proBNP-guided therapy showed no benefit over high-quality usual care
- Earlier trials like STARS-BNP and PROTECT showed NP-guided therapy reduced cardiovascular events, but in settings where usual care was less intensive
- Meta-analyses suggest NP-guided therapy reduces hospitalizations and mortality in patients under 75 years, but not in older patients
- Sacubitril/valsartan raises BNP levels through neprilysin inhibition while lowering NT-proBNP, complicating BNP-guided strategies
- A 2023 joint scientific statement from three international heart failure societies supports serial NP measurement for prognostic assessment but stops short of mandating specific treatment targets
- A 2026 study showed predischarge NT-proBNP levels independently predict treatment optimization success in acute heart failure
What Is Natriuretic Peptide-Guided Therapy?
Standard heart failure management follows clinical guidelines: start medications, titrate to target doses, monitor symptoms, adjust if the patient worsens. Natriuretic peptide-guided therapy adds a biochemical layer. Clinicians draw blood at regular intervals, measure BNP or NT-proBNP, and use the result to decide whether to intensify treatment, maintain the current regimen, or investigate new problems.
The rationale is that peptide levels change before symptoms do. A rising NT-proBNP can signal fluid overload, worsening cardiac function, or medication nonadherence days to weeks before a patient feels worse. Conversely, falling levels suggest successful treatment. The approach converts an objective laboratory value into an actionable treatment signal.[1]
Most guided-therapy protocols use NT-proBNP rather than BNP. NT-proBNP has a longer half-life, is less affected by acute fluctuations, and is not directly cleared by neprilysin. This distinction became critical after sacubitril/valsartan entered clinical practice.[2]
Common target thresholds vary by trial: NT-proBNP below 1,000 pg/mL (GUIDE-IT, PROTECT), below 400 pg/mL (BATTLESCARRED), or a percentage reduction from baseline (PRIMA II targeted >30% reduction). No universal consensus exists on the optimal target value.
The Clinical Trials: A Mixed Record
Positive Trials
The STARS-BNP trial (2007) randomized 220 patients with heart failure and reduced ejection fraction (HFrEF) to BNP-guided therapy targeting BNP below 100 pg/mL versus usual care. The guided group had significantly fewer heart failure-related deaths and hospital admissions over 15 months. The guided group also received more aggressive up-titration of ACE inhibitors and beta-blockers.[3]
The PROTECT study (2009) randomized 151 patients with HFrEF to NT-proBNP-guided therapy targeting levels below 1,000 pg/mL versus usual care. Over 10 months, the guided group had significantly fewer total cardiovascular events (mean 0.64 vs. 1.16 per patient). Guided patients were more frequently prescribed aldosterone antagonists and had greater improvement in quality of life.[4]
Age-Dependent Results
The BATTLESCARRED trial (2010) and TIME-CHF trial (2009) both found that NP-guided therapy reduced mortality, but only in patients under 75 years old. In patients over 75, the strategy showed no benefit. This age cutoff has been replicated in meta-analyses and may reflect the difficulty of medication intensification in elderly patients with multiple comorbidities, renal impairment, and polypharmacy.
The GUIDE-IT Disappointment
The GUIDE-IT trial (2017) was designed to settle the question definitively. It enrolled 894 patients with HFrEF (ejection fraction ≤40%, NT-proBNP ≥2,000 pg/mL or prior BNP ≥400 pg/mL) across 45 North American sites. Patients were randomized to NT-proBNP-guided therapy targeting levels below 1,000 pg/mL versus usual care.[5]
The trial was stopped early by the data safety monitoring board because an interim analysis showed no possibility of demonstrating benefit. At the time of termination, there was no significant difference in the primary endpoint (composite of cardiovascular death and heart failure hospitalization), no difference in quality of life, and no difference in medication doses between groups.
The result surprised many cardiologists, but the reason became clear in post-hoc analysis: the "usual care" in GUIDE-IT was exceptionally good. Patients in both groups were seen nearly a dozen times in the first year, managed at tertiary care centers by experienced heart failure specialists. Both groups achieved similar medication up-titration. The biomarker added no incremental value when clinicians were already practicing at a high level.[6]
Acute Heart Failure: PRIMA II
The PRIMA II trial tested NT-proBNP-guided therapy in a different context: acute decompensated heart failure. The target was an NT-proBNP reduction of greater than 30% from admission to discharge. The trial found no improvement in 6-month clinical outcomes compared to usual care, and the guided strategy did not change treatment patterns during hospitalization.
What Meta-Analyses Show
Several meta-analyses have attempted to reconcile the conflicting trial results.
A 2018 systematic review combining individual participant data from multiple trials found that NP-guided therapy reduced all-cause mortality (hazard ratio 0.62) and heart failure hospitalization (hazard ratio 0.80) in patients under 75 years. In patients 75 and older, neither endpoint was significantly improved. The effect appeared strongest when the gap between usual care quality and guideline-recommended care was largest.[7]
This meta-analytic finding reframes the question. NP-guided therapy may not beat expert heart failure management, but it may systematically improve care in settings where guideline adherence is suboptimal. In community practice, primary care, or health systems with less specialized heart failure management, serial NP monitoring could drive the medication intensification that tertiary centers achieve without it.
The Sacubitril/Valsartan Complication
The introduction of sacubitril/valsartan (Entresto) in 2015 created a specific challenge for BNP-guided therapy. Sacubitril inhibits neprilysin, the enzyme that degrades natriuretic peptides. This means BNP levels rise after starting sacubitril/valsartan, even though the drug is therapeutically beneficial. A clinician using BNP as a guide would see rising levels and potentially withhold a life-saving medication.
NT-proBNP, which is not a neprilysin substrate, decreases with sacubitril/valsartan treatment. This pharmacological distinction made NT-proBNP the preferred biomarker for any guided-therapy strategy in patients taking sacubitril/valsartan.[8]
A 2022 reassessment asked whether BNP remains a valid heart failure biomarker in the sacubitril/valsartan era. The conclusion was nuanced: BNP retains diagnostic and prognostic value, but its interpretation requires knowledge of the patient's medication list. This added complexity has pushed most contemporary guided-therapy protocols toward NT-proBNP exclusively.[9]
Current Guideline Positions
A 2023 joint scientific statement from the Heart Failure Association of the European Society of Cardiology, the Heart Failure Society of America, and the Japanese Heart Failure Society provided the most comprehensive consensus on natriuretic peptides in heart failure management.[10]
The statement supports:
- Serial NP measurements for prognostic assessment and monitoring treatment response
- Using NP trends (rising or falling) to inform clinical decisions
- NP measurement at key transitions: diagnosis, hospitalization, discharge, and outpatient follow-up
The statement stops short of endorsing a specific target-based guided-therapy protocol for all patients. It acknowledges the benefit in younger patients but recognizes that GUIDE-IT cast doubt on the strategy's incremental value in well-managed populations.
A 2025 Eurasian-Turkish guideline further formalized the role of natriuretic peptides in primary care, recommending NT-proBNP as a first-line screening tool for heart failure in patients presenting with dyspnea, with age-adjusted cutoffs and structured referral pathways.[11]
Emerging Applications
NT-proBNP and Treatment Optimization After Discharge
A 2026 study by Polovina and colleagues examined predischarge NT-proBNP levels in patients hospitalized for acute heart failure. Higher predischarge NT-proBNP independently predicted failure to achieve guideline-directed medical therapy optimization at follow-up, suggesting that the biomarker identifies patients who need more intensive outpatient management.[12]
Semaglutide and NT-proBNP in HFpEF
The STEP-HFpEF trial demonstrated that semaglutide reduced NT-proBNP levels in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). A 2024 analysis of the trial data found that NT-proBNP reductions correlated with improvements in symptoms, physical function, and exercise capacity, supporting the biomarker's value as a surrogate endpoint in HFpEF trials.[13]
Machine Learning and NP Interpretation
A 2025 study applied machine learning algorithms to optimize the diagnostic performance of natriuretic peptides, incorporating patient characteristics such as age, sex, BMI, and renal function into NP interpretation. The approach improved diagnostic accuracy for heart failure compared to fixed cutoff values, pointing toward personalized biomarker thresholds rather than one-size-fits-all targets.[14]
Heart Failure With Recovered Ejection Fraction
A 2025 study examined the prognostic value of natriuretic peptide levels in patients whose ejection fraction improved with treatment (HFrecEF). In these patients, persistently elevated NP levels despite improved cardiac function predicted higher rates of rehospitalization and death, suggesting that NP monitoring remains valuable even after apparent recovery.[15]
The Bottom Line on NP-Guided Therapy
The concept of using a blood test to tune heart failure medications is sound in principle. Natriuretic peptides directly reflect cardiac wall stress, respond to effective treatment, and predict clinical outcomes. The problem is not with the biomarker but with the clinical context.
In settings where heart failure specialists see patients frequently, follow guidelines rigorously, and titrate medications aggressively, adding NP targets provides little additional benefit. In settings where care is less systematic, NP monitoring may drive the treatment intensification that guidelines recommend but practice often fails to deliver.
For how natriuretic peptides protect the heart and kidneys beyond their biomarker role, and for the cautionary story of nesiritide, the recombinant BNP that failed as a therapy, these sibling articles provide deeper context.
The Bottom Line
Natriuretic peptide-guided therapy uses serial BNP or NT-proBNP measurements to optimize heart failure medications. Earlier trials showed benefits, particularly in patients under 75, but the GUIDE-IT trial found no advantage over high-quality usual care. Current guidelines support serial NP monitoring for prognostic assessment and clinical decision-making but do not mandate specific target-based protocols. The strategy may be most valuable in settings where guideline adherence is suboptimal.